TMP-SMX is the first choice drug to prevent Pneumocystis jiroveci pneumonia
(PCP) in hemato-oncology patients. The utilization of alternative drugs (Pentamidine – Dapsone) was
suggested in some protocols in hemato-oncology. It seems that there is a
n increase in the utilization of
alternative drugs. The aim of the study was to evaluate the utilization of different drugs to prevent PCP
and to identify the reasons which lead to the utilization of alternative drugs.
